URS
CRSP icon

Utah Retirement Systems’s CRISPR Therapeutics CRSP Stock Holding History

Utah Retirement Systems’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-8,700
Closed -$354K – 978
2022
Q4 		$354K Hold
8,700
– – 0.01% 837
2022
Q3 		$569K Hold
8,700
– – 0.01% 796
2022
Q2 		$529K Hold
8,700
– – 0.01% 817
2022
Q1 		$546K Hold
8,700
– – 0.01% 836
2021
Q4 		$659K Hold
8,700
– – 0.01% 834
2021
Q3 		$974K Sell
8,700
-700
-7% -$87.9K 0.01% 784
2021
Q2 		$1.52M Buy
9,400
+800
+9% +$97.3K 0.02% 683
2021
Q1 		$1.05M Buy
+8,600
New +$1.3M 0.01% 768

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Utah Retirement Systems's CRSP Position: Q1 2023 in Review

Utah Retirement Systems sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 8,700 shares — an estimated $354K sold.

Utah Retirement Systems first reported a position in CRSP in Q1 2021 and held it in 8 quarters. The position peaked at $1.52M in Q2 2021. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

  • Utah Retirement Systems reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Utah Retirement Systems sold 8,700 CRISPR Therapeutics shares in Q1 2023, an estimated $354K.
  • Utah Retirement Systems first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 8 quarters.
  • Utah Retirement Systems's CRISPR Therapeutics position peaked at $1.52M in Q2 2021.
  • 381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Utah Retirement Systems's 13F filing for Q1 2023, filed 16 May 2023.